High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients

© 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology..

Severe acute respiratory syndrome coronavirus 2 is responsible for coronavirus disease 2019 (COVID-19). While COVID-19 is often benign, a subset of patients develops severe multilobar pneumonia that can progress to an acute respiratory distress syndrome. There is no cure for severe COVID-19 and few treatments significantly improved clinical outcome. Dexamethasone and possibly aspirin, which directly/indirectly target the biosynthesis/effects of numerous lipid mediators are among those options. Our objective was to define if severe COVID-19 patients were characterized by increased bioactive lipids modulating lung inflammation. A targeted lipidomic analysis of bronchoalveolar lavages (BALs) by tandem mass spectrometry was done on 25 healthy controls and 33 COVID-19 patients requiring mechanical ventilation. BALs from severe COVID-19 patients were characterized by increased fatty acids and inflammatory lipid mediators. There was a predominance of thromboxane and prostaglandins. Leukotrienes were also increased, notably LTB4 , LTE4 , and eoxin E4 . Monohydroxylated 15-lipoxygenase metabolites derived from linoleate, arachidonate, eicosapentaenoate, and docosahexaenoate were also increased. Finally yet importantly, specialized pro-resolving mediators, notably lipoxin A4 and the D-series resolvins, were also increased, underscoring that the lipid mediator storm occurring in severe COVID-19 involves pro- and anti-inflammatory lipids. Our data unmask the lipid mediator storm occurring in the lungs of patients afflicted with severe COVID-19. We discuss which clinically available drugs could be helpful at modulating the lipidome we observed in the hope of minimizing the deleterious effects of pro-inflammatory lipids and enhancing the effects of anti-inflammatory and/or pro-resolving lipid mediators.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

FASEB journal : official publication of the Federation of American Societies for Experimental Biology - Vol. 35, No. 6 (2021), p. e21666

Language:

English

Contributors:

Archambault, Anne-Sophie
Zaid, Younes
Rakotoarivelo, Volatiana
Turcotte, Caroline
Doré, Étienne
Dubuc, Isabelle
Martin, Cyril
Flamand, Olivier
Amar, Youssef
Cheikh, Amine
Fares, Hakima
El Hassani, Amine
Tijani, Youssef
Côté, Andréanne
Laviolette, Michel
Boilard, Éric
Flamand, Louis
Flamand, Nicolas

Links:

Volltext

Keywords:

*COVID-19
*Lung
14-cysteinyl-15-hydroxy-5,8,10,12-eicosatetraenoic acid
1HGW4DR56D
75715-89-8
Adult
COVID-19
Clinical Trial
Docosanoids
Eicosanoids
Eoxins
Female
Humans
Journal Article
Leukotriene B4
Leukotriene E4
Lipoxin A4
Lipoxins
Male
Middle Aged
SARS-CoV-2
Specialized pro-resolving mediators
Thromboxane

Notes:

Date Completed 31.05.2021

Date Revised 31.05.2021

published: Print

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1096/fj.202100540R

PMID:

34033145

PPN (Catalogue-ID):

NLM32697220X